Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
11
×
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
immunotherapy
11
×
indiana blog main
indiana top stories
life sciences
national
11
×
national blog main
national top stories
new york blog main
11
×
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
11
×
wisconsin top stories
novartis
bristol-myers squibb
merck
pfizer
abbvie
amgen
cancer
clinical trials
fda
gilead sciences
glaxosmithkline
roche
What
roundup
bio
annual
cancer
drug
conference
medical
society
ash
celgene
clinical
days
disease
esmo
european
lung
medicine
nash
new
news
oncology
patients
price
today
abbvie’s
according
acquisitions
advantages
ahead
airport
akcea
albert
alzheimer's
american
apocalypse
approval
bad
bar
barcelona
beds
Language
unset
unknown
Current search:
immunotherapy
×
national
×
" wisconsin blog main "
×
" boston blog main "
×
" new york blog main "
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front